Syros Pharmaceuticals, Inc

(NASDAQ:SYRS)

Latest On Syros Pharmaceuticals, Inc (SYRS):

Date/Time Type Description Signal Details
2023-05-11 10:55 ESTNewsSyros Pharmaceuticals, Inc. (SYRS) Q1 2023 Earnings Call TranscriptN/A
2023-05-10 07:36 ESTNewsSyros Pharmaceuticals GAAP EPS of -$0.85 beats by $0.20, revenue of $3M misses by $0.3MN/A
2023-04-06 19:30 ESTNewsSyros Pharmaceuticals files for $250M mixed shelf offering - filingN/A
2023-03-13 19:21 ESTNewsRAPT Therapeutics, Repare Therapeutics among biotechs to disclose exposure to Silicon Valley BankN/A
2023-03-02 22:12 ESTNewsSyros Pharmaceuticals GAAP EPS of -$0.17 beats by $1.13N/A
2023-03-02 22:12 ESTNewsSyros Pharmaceuticals, Inc. (SYRS) Q4 2022 Earnings Call TranscriptN/A
2023-03-01 16:52 ESTNewsSyros Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-02-08 12:47 ESTNewsSyros: Multiple Shots On Goal In Blood Cancer SpaceN/A
2023-01-26 12:29 ESTNewsSyros stock rises as tamibarotene gets FDA fast track status for rare blood cancerN/A
2023-01-15 01:56 ESTNewsSyros Pharmaceuticals A Buy Given Stock Price And Pipeline Potential (Rating Upgrade)N/A
2022-11-14 15:38 ESTNewsSyros Pharmaceuticals GAAP EPS of -$3.21 beats by $0.30, revenue of $3.9M misses by $1.28MN/A
2022-11-14 15:37 ESTNewsSyros Pharmaceuticals, Inc. (SYRS) Q3 2022 Earnings Call TranscriptN/A
2022-11-11 17:30 ESTNewsSyros Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-09-20 22:39 ESTNewsSyros Pharmaceuticals: A Major Vote Of Confidence From InsidersN/A
2022-09-15 22:41 ESTNewsSyros, Tyme Technologies jump more than 20% after hours as shareholders approve mergerN/A
2022-09-13 18:10 ESTNewsSyros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609N/A
2022-08-10 06:03 ESTNewsSyros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-10 06:03 ESTNewsSyros Pharma stock slips after mixed Q2 results & a significant prior runup in sharesN/A
2022-08-09 08:23 ESTNewsSyros Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-08-09 08:23 ESTNewsSyros Pharmaceuticals GAAP EPS of -$0.54 misses by $0.13, revenue of $6.28M beats by $1.5MN/A
2022-08-04 02:17 ESTNewsSyros climbs 74% as EMA backs orphan drug designation for lead candidateN/A
2022-05-16 19:40 ESTNewsSyros Pharmaceuticals GAAP EPS of -$0.40 beats by $0.07, revenue of $5.47M beats by $0.55MN/A
2022-05-16 19:39 ESTNewsSyros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-14 03:57 ESTNewsSyros Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-03-16 12:27 ESTNewsSyros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-15 09:55 ESTNewsSyros Pharmaceuticals GAAP EPS of -$0.38 beats by $0.08, revenue of $78M beats by $73.16MN/A
2022-03-14 17:05 ESTNewsSyros Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-02-03 01:25 ESTNewsSyros rises 13% as tamibarotene gets FDA orphan drug status for myelodysplastic syndromeN/A
2022-01-11 18:32 ESTNewsSyros outlines clinical updates and 2022 goalsN/A
2021-11-19 20:21 ESTNewsSyros Pharmaceuticals Is A Buy As New Trials StartN/A
2021-11-05 13:55 ESTNewsSyros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-04 16:56 ESTNewsSyros Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-10-12 13:29 ESTNewsSyros Pharmaceuticals names Jason Haas as CFON/A
2021-09-30 00:03 ESTNewsSyros gets dosing underway in confirmation study of SY-2101 in acute promyelocytic leukemiaN/A
2021-09-28 02:29 ESTNewsSyros Pharmaceuticals (SYRS) Investor PresentationN/A
2021-09-22 07:31 ESTNewsSyros Pharmaceuticals EPS beats by $0.03, beats on revenueN/A
2021-09-22 07:08 ESTNewsSyros Pharmaceuticals posts new data from early-stage SY-5609 cancer trialN/A
2021-09-10 08:27 ESTNewsSyros adds Deborah Dunsire to board of directorsN/A
2021-08-08 20:27 ESTNewsSyros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-05 13:50 ESTNewsSyros Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call PresentationN/A
2021-07-22 02:59 ESTNewsSyros Pharma up 18% day after ARK Innovation dumps sharesN/A
2021-07-22 02:36 ESTNewsSyros: Pivotal Trial In MDS OngoingN/A
2021-05-06 19:44 ESTNewsSyros Pharmaceuticals EPS beats by $0.24, beats on revenueN/A
2021-03-23 10:37 ESTNewsRevisiting Syros PharmaceuticalsN/A
2021-03-08 12:35 ESTAnalyst RatingThe Analyst Target Price has decreased from $17.14 to $16.57.Neutral
2021-03-06 02:47 ESTNewsSyros Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call PresentationN/A
2021-03-06 00:52 ESTFinancialsCompany financials have been released.Neutral
2021-03-05 12:27 ESTEarnings EstimateAn EPS average of -$1.72 is estimated for the 2022 year.Sell
2021-03-05 12:27 ESTEarnings EstimateAn EPS average of -$0.38 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-05 05:48 ESTNewsSyros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2020 Results - Earnings Call TranscriptN/A

About Syros Pharmaceuticals, Inc (SYRS):

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

SYRS Quotes by TradingView

See Advanced Chart

General

  • Name Syros Pharmaceuticals, Inc
  • Symbol SYRS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 103
  • Fiscal Year EndDecember
  • IPO Date2016-06-30
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.syros.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 27.25
  • Price/Book (Most Recent Quarter) 6.08
  • Enterprise Value Revenue 29.33
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.77
  • Next Year EPS Estimate -$1.75
  • Next Quarter EPS Estimate -$0.43
  • Operating Margin -545%
  • Return on Assets -28%
  • Return on Equity -99%
  • Revenue 15.09 million
  • Earnings Per Share -$1.95
  • Revenue Per Share $0.33
  • Gross Profit 15.09 million
  • Quarterly Earnings Growth 1021.9%
View More

Highlights

  • Market Capitalization 561.53 million
  • EBITDA -70088000
  • PE Ratio -0.33
  • Analyst Target Price $16.57
  • Book Value Per Share $1.61
View More

Share Statistics

  • Shares Outstanding 61.64 million
  • Shares Float 56.72 million
  • % Held by Insiders 1238%
  • % Held by Institutions 101.58%
  • Shares Short 4.03 million
  • Shares Short Prior Month 3.64 million
  • Short Ratio 6.63
  • Short % of Float 10%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • Beta 1.95
  • 52 Week High $15.65
  • 52 Week Low $4.88
  • 50 Day Moving Average 10.18
  • 200 Day Moving Average 9.92
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Syros Pharmaceuticals, Inc (SYRS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Syros Pharmaceuticals, Inc (SYRS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$N/A-$0.62-$0.51-20.55%
2020-09-302020-11-05$N/A-$0.43-$0.40-7.05%
2020-06-302020-08-06$N/A-$0.38-$0.429.52%
2020-03-312020-05-07$N/A-$0.39-$0.4716.31%
2019-12-312020-03-05$508000-$0.46-$0.484.96%
2019-09-302019-11-12$558000-$0.47-$0.482.08%
2019-06-302019-08-01$462000-$0.47-$0.41-14.63%
2019-03-312019-05-01$454000-$0.49-$0.5612.5%
2018-12-312019-03-07$893000-$0.54-$0.49-9.31%
2018-09-302018-11-01$412000-$0.47-$0.45-3.52%
2018-06-302018-08-07$375000-$0.43-$0.5013.43%
2018-03-312018-05-10$370000-$0.48-$0.44-8.47%
2017-12-312018-03-12$1.1 million-$0.58-$0.57-1.31%
2017-09-302017-11-08$N/A-$0.53-$0.541.4%
2017-06-302017-08-09$-1101000-$0.52-$0.5911.37%
2017-03-312017-05-15$1.1 million-$0.49-$0.6423.83%
2016-12-312017-03-20$317000-$0.47-$0.6426.1%
2016-09-302016-11-14$N/A-$0.65-$0.49-32.65%
2016-06-302016-08-15$N/A-$0.59-$0.53-12.76%

Syros Pharmaceuticals, Inc (SYRS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A N/A N/A N/A 14.28 million
Income Before Tax N/A N/A N/A N/A -19.73 million
Selling General Administrative N/A N/A N/A N/A 6.4 million
Gross Profit N/A N/A N/A N/A 508000
Ebit N/A N/A N/A N/A -20.17 million
Operating Income N/A N/A N/A N/A -20.17 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A 508000
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A 441000
Net Income From Continuing Operations N/A N/A N/A N/A -19.73 million
Net Income Applicable to Common Shares -30.13 million -19.49 million -17.2 million -17.23 million -19.73 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A 25 million -54.57 million
Change to Liabilities 829000 -1.75 million -1.96 million 21.05 million 1.09 million
Total Cash Flow from Investing Activities -522000 4.01 million 43.2 million 16.95 million -57.14 million
Net Borrowings -61000 -74000 19.66 million -56000 -55000
Total Cash Flow from Financial Activities N/A N/A N/A 1.09 million -12000
Change to Operating Activities 534000 1.48 million -2.28 million 4.51 million 4.65 million
Change in Cash N/A N/A N/A 7.44 million -68.38 million
Total Cash from Operating Activities -15.26 million -12.43 million 246000 -10.6 million -11.22 million
Depreciation N/A N/A N/A 898000 643000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A -20.16 million N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 2.72 million 2.73 million 2.41 million 2.82 million 2.19 million
Capital Expenditures N/A N/A N/A 8.16 million 2.57 million
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A N/A N/A N/A 70.79 million
Total Stockholder Equity N/A N/A N/A N/A 79.18 million
Other Current Liabilities 12.21 million 11.18 million N/A N/A 5.74 million
Total Assets N/A N/A N/A N/A 149.98 million
Common Stock 56000 45000 45000 45000 43000
Other Current Assets N/A N/A N/A N/A 290000
Retained Earnings -377.02 million -346.89 million -327.41 million -310.21 million -292.98 million
Other Liabilities 29.59 million 14.22 million 16.74 million 20.68 million 22.64 million
Other Assets 5.05 million 4.1 million 4.13 million 3.86 million 3.58 million
Cash N/A N/A N/A N/A 41.44 million
Total Current Liabilities 28.62 million 28.06 million N/A N/A 23.52 million
Other Stockholder Equity N/A N/A N/A 3000 24000
Property, Plant & Equipment 29.64 million 30.68 million 31.24 million 31.84 million 31.89 million
Total Current Assets 178.56 million 98.56 million N/A N/A 114.51 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 90.55 million 45.94 million 62.41 million 76.54 million 79.18 million
Short Term Investments N/A N/A N/A N/A 49.98 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 3.6 million 4.94 million N/A N/A 5.85 million

Syros Pharmaceuticals, Inc (SYRS) Chart:

Syros Pharmaceuticals, Inc (SYRS) News:

Below you will find a list of latest news for Syros Pharmaceuticals, Inc (SYRS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Syros Pharmaceuticals, Inc (SYRS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-03-210.50.05CALL0 60FALSE00
2025-03-2110.1CALL0 2626.59FALSE00
2025-03-211.50CALL0 00FALSE00
2025-03-2120CALL0 00FALSE00
2025-03-212.50CALL0 0621.33FALSE00
2025-03-2150CALL0 00FALSE00
2025-03-217.50CALL0 00FALSE00
2025-03-210.50PUT0 00TRUE00
2025-03-2110.8PUT0 10TRUE00
2025-03-211.50PUT0 00TRUE00
2025-03-2120PUT0 0619.87TRUE00
2025-03-212.50PUT0 00TRUE00
2025-03-2150PUT0 01024.81TRUE00
2025-03-217.50PUT0 01090.36TRUE00
2025-04-170.50.1CALL1 6559.81FALSE0.10
2025-04-1710.05CALL0 110FALSE00
2025-04-171.50CALL0 00FALSE00
2025-04-1720CALL0 00FALSE00
2025-04-172.50.04CALL0 699446.82FALSE00
2025-04-1750.01CALL0 1212609.61FALSE00
2025-04-177.50.05CALL0 2000FALSE00
2025-04-170.50PUT0 0895.16TRUE00
2025-04-1710PUT0 0224.79TRUE00
2025-04-171.50PUT0 00TRUE00
2025-04-1720PUT0 0458.8TRUE00
2025-04-172.52.3PUT0 402906.85TRUE00
2025-04-1750PUT0 00TRUE00
2025-04-177.55.49PUT0 00TRUE00
2025-07-180.50.15CALL0 273280.65FALSE00
2025-07-1810.05CALL0 250FALSE00
2025-07-181.50CALL0 0493.24FALSE00
2025-07-1820CALL0 00FALSE00
2025-07-182.50.05CALL0 2057335.17FALSE00
2025-07-1850.1CALL0 67430.7FALSE00
2025-07-187.50.15CALL0 3452.12FALSE00
2025-07-180.50.15PUT0 1444.8TRUE00
2025-07-1810PUT0 00TRUE00
2025-07-181.50PUT0 00TRUE00
2025-07-1820PUT0 00TRUE00
2025-07-182.52.22PUT0 80TRUE00
2025-07-1850PUT0 00TRUE00
2025-07-187.50PUT0 00TRUE00
2025-10-170.50CALL0 00FALSE00
2025-10-1710CALL0 00FALSE00
2025-10-171.50CALL0 00FALSE00
2025-10-1720CALL0 00FALSE00
2025-10-172.50CALL0 00FALSE00
2025-10-1750CALL0 00FALSE00
2025-10-177.50CALL0 00FALSE00
2025-10-170.50PUT0 0148.62TRUE00
2025-10-1710PUT0 00TRUE00
2025-10-171.50PUT0 0230.83TRUE00
2025-10-1720PUT0 00TRUE00
2025-10-172.50PUT0 0427.93TRUE00
2025-10-1750PUT0 0440.6TRUE00
2025-10-177.50PUT0 0494.07TRUE00

Latest SYRS Trades:

Date Shares Price
Jun 13, 2022 7:54 PM EST100$0.9506
Jun 13, 2022 7:55 PM EST100$0.9524
Jun 13, 2022 7:58 PM EST100$0.9525
Jun 13, 2022 7:59 PM EST100$0.9549
Jun 13, 2022 7:59 PM EST100$0.9547

Syros Pharmaceuticals, Inc (SYRS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000110465920076997/0001104659-20-076997-index.htm
2018-08-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1556263/000000000018025231/0000000000-18-025231-index.htm
2018-09-17UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1556263/000000000018028977/0000000000-18-028977-index.htm
2020-06-17UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1556263/000000000020005409/0000000000-20-005409-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000021545719006653/0000215457-19-006653-index.htm
2019-05-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000021545719007862/0000215457-19-007862-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000031506619001317/0000315066-19-001317-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000031506620001218/0000315066-20-001218-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000083423720008081/0000834237-20-008081-index.htm
2020-04-02SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000089914020000230/0000899140-20-000230-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000089924320005283/0000899243-20-005283-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000095010320002665/0000950103-20-002665-index.htm
2019-03-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000101297519000225/0001012975-19-000225-index.htm
2019-03-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000101297519000242/0001012975-19-000242-index.htm
2019-07-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000101297519000489/0001012975-19-000489-index.htm
2018-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1556263/000104746918003194/0001047469-18-003194-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000107261319000102/0001072613-19-000102-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000107261320000096/0001072613-20-000096-index.htm
2018-03-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000110465918017641/0001104659-18-017641-index.htm
2018-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1556263/000110465918026874/0001104659-18-026874-index.htm
2018-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000110465918040331/0001104659-18-040331-index.htm
2018-08-2410-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1556263/000110465918053548/0001104659-18-053548-index.htm
2018-08-2410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1556263/000110465918053549/0001104659-18-053549-index.htm
2018-08-2410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1556263/000110465918053550/0001104659-18-053550-index.htm
2018-08-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1556263/000110465918053551/0001104659-18-053551-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000110465918058596/0001104659-18-058596-index.htm
2018-11-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000110465918068768/0001104659-18-068768-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000110465919000970/0001104659-19-000970-index.htm
2019-01-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000110465919001621/0001104659-19-001621-index.htm
2019-04-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000110465919020868/0001104659-19-020868-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000110465920021152/0001104659-20-021152-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000110465920076997/0001104659-20-076997-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000110465920081190/0001104659-20-081190-index.htm
2020-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000110465920096870/0001104659-20-096870-index.htm
2020-10-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000110465920113856/0001104659-20-113856-index.htm
2019-09-06SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000114036119016285/0001140361-19-016285-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000114036120002960/0001140361-20-002960-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000114420419007784/0001144204-19-007784-index.htm
2018-06-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000117911018008616/0001179110-18-008616-index.htm
2018-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000117911018008617/0001179110-18-008617-index.htm
2018-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000117911018008618/0001179110-18-008618-index.htm
2018-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000117911018008619/0001179110-18-008619-index.htm
2018-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000117911018008621/0001179110-18-008621-index.htm
2018-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000117911018008622/0001179110-18-008622-index.htm
2018-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000117911018008623/0001179110-18-008623-index.htm
2018-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000117911018008624/0001179110-18-008624-index.htm
2018-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000117911018008625/0001179110-18-008625-index.htm
2018-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000117911018013361/0001179110-18-013361-index.htm
2019-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1556263/000119312519039121/0001193125-19-039121-index.htm
2019-03-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1556263/000119312519066569/0001193125-19-066569-index.htm
2019-04-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1556263/000119312519097897/0001193125-19-097897-index.htm
2019-04-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1556263/000119312519097903/0001193125-19-097903-index.htm
2019-04-05FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1556263/000119312519098385/0001193125-19-098385-index.htm
2019-04-05FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1556263/000119312519098389/0001193125-19-098389-index.htm
2019-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312519099438/0001193125-19-099438-index.htm
2019-04-08424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1556263/000119312519099440/0001193125-19-099440-index.htm
2019-04-08424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1556263/000119312519099442/0001193125-19-099442-index.htm
2019-04-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312519115861/0001193125-19-115861-index.htm
2019-04-25DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1556263/000119312519118082/0001193125-19-118082-index.htm
2019-04-25DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1556263/000119312519118086/0001193125-19-118086-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312519171211/0001193125-19-171211-index.htm
2019-10-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312519268940/0001193125-19-268940-index.htm
2019-10-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312519273138/0001193125-19-273138-index.htm
2019-10-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312519274743/0001193125-19-274743-index.htm
2019-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312519283323/0001193125-19-283323-index.htm
2019-12-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312519303728/0001193125-19-303728-index.htm
2019-12-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312519316774/0001193125-19-316774-index.htm
2019-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312519319786/0001193125-19-319786-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312520005784/0001193125-20-005784-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312520034397/0001193125-20-034397-index.htm
2020-03-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1556263/000119312520062209/0001193125-20-062209-index.htm
2020-03-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1556263/000119312520065261/0001193125-20-065261-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1556263/000119312520121908/0001193125-20-121908-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1556263/000119312520121912/0001193125-20-121912-index.htm
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312520167170/0001193125-20-167170-index.htm
2020-06-12S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1556263/000119312520167717/0001193125-20-167717-index.htm
2020-06-18CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1556263/000119312520171851/0001193125-20-171851-index.htm
2020-06-23424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1556263/000119312520176648/0001193125-20-176648-index.htm
2020-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312520241676/0001193125-20-241676-index.htm
2020-10-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000119312520275988/0001193125-20-275988-index.htm
2019-04-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000119380519000352/0001193805-19-000352-index.htm
2019-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119010282/0001209191-19-010282-index.htm
2019-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119010283/0001209191-19-010283-index.htm
2019-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119010284/0001209191-19-010284-index.htm
2019-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119010285/0001209191-19-010285-index.htm
2019-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119010287/0001209191-19-010287-index.htm
2019-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119010291/0001209191-19-010291-index.htm
2019-06-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119036350/0001209191-19-036350-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119036355/0001209191-19-036355-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119036358/0001209191-19-036358-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119036359/0001209191-19-036359-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119036361/0001209191-19-036361-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119036364/0001209191-19-036364-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119036365/0001209191-19-036365-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119036366/0001209191-19-036366-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119036368/0001209191-19-036368-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119036369/0001209191-19-036369-index.htm
2019-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119046516/0001209191-19-046516-index.htm
2019-11-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119056026/0001209191-19-056026-index.htm
2019-12-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119061429/0001209191-19-061429-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119061430/0001209191-19-061430-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919119061818/0001209191-19-061818-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120009591/0001209191-20-009591-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120009593/0001209191-20-009593-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120009594/0001209191-20-009594-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120009595/0001209191-20-009595-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120009599/0001209191-20-009599-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120009600/0001209191-20-009600-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120024775/0001209191-20-024775-index.htm
2020-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120028871/0001209191-20-028871-index.htm
2020-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120029763/0001209191-20-029763-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120035964/0001209191-20-035964-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120035965/0001209191-20-035965-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120035966/0001209191-20-035966-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120035967/0001209191-20-035967-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120035968/0001209191-20-035968-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120035970/0001209191-20-035970-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120035971/0001209191-20-035971-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120037001/0001209191-20-037001-index.htm
2020-07-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120041574/0001209191-20-041574-index.htm
2020-07-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120042796/0001209191-20-042796-index.htm
2020-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120047501/0001209191-20-047501-index.htm
2020-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120047504/0001209191-20-047504-index.htm
2020-09-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120049802/0001209191-20-049802-index.htm
2020-09-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120049803/0001209191-20-049803-index.htm
2020-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120050618/0001209191-20-050618-index.htm
2020-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120055059/0001209191-20-055059-index.htm
2020-10-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1556263/000120919120055334/0001209191-20-055334-index.htm
2019-09-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1556263/000121465919005720/0001214659-19-005720-index.htm
2018-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1556263/000141057818000568/0001410578-18-000568-index.htm
2018-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1556263/000155837018004563/0001558370-18-004563-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1556263/000155837018006522/0001558370-18-006522-index.htm
2018-11-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1556263/000155837018008210/0001558370-18-008210-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1556263/000156459019006610/0001564590-19-006610-index.htm
2019-05-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1556263/000156459019014558/0001564590-19-014558-index.htm
2019-08-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1556263/000156459019027692/0001564590-19-027692-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1556263/000156459019042566/0001564590-19-042566-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1556263/000156459020008795/0001564590-20-008795-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1556263/000156459020022351/0001564590-20-022351-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1556263/000156459020037228/0001564590-20-037228-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1556263/000156459020051239/0001564590-20-051239-index.htm
2020-06-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1556263/999999999520001499/9999999995-20-001499-index.htm
2018-04-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1556263/999999999718005185/9999999997-18-005185-index.htm
2018-11-19CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1556263/999999999718009025/9999999997-18-009025-index.htm
2019-05-02CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1556263/999999999719003684/9999999997-19-003684-index.htm

Syros Pharmaceuticals, Inc (SYRS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Syros Pharmaceuticals, Inc (SYRS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1238%
Institutional Ownership: 10158%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-02-18Eric R OlsonChief Scientific OfficerSell1,446.007.3810,674.080.00https://www.sec.gov/Archives/edgar/data/1556263/000089924320005283/0000899243-20-005283-index.htm
2020-07-07Eric R OlsonChief Scientific OfficerSell1,753.0011.7220,538.500.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120041574/0001209191-20-041574-index.htm
2020-08-17Eric R OlsonChief Scientific OfficerSell4,963.0013.0064,519.000.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120047504/0001209191-20-047504-index.htm
2020-08-18Eric R OlsonChief Scientific OfficerSell10,787.0013.00140,231.000.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120047504/0001209191-20-047504-index.htm
2020-05-13Mark J AllesDirectorBuy10,000.008.8688,590.0010,000.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120028871/0001209191-20-028871-index.htm
2019-02-12Jeremy P. SpringhornChief Business OfficerBuy87,000.00102,000.00https://www.sec.gov/Archives/edgar/data/1556263/000120919119010291/0001209191-19-010291-index.htm
2020-08-18Eric R OlsonChief Scientific OfficerBuy10,787.001.0110,894.8710,787.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120047504/0001209191-20-047504-index.htm
2020-08-18SRINIVAS AKKARAJUDirectorSell158,583.0013.102,076,723.681,274,616.00https://www.sec.gov/Archives/edgar/data/1556263/000110465920096870/0001104659-20-096870-index.htm
2020-08-17SRINIVAS AKKARAJUDirectorSell744.0013.009,672.001,433,199.00https://www.sec.gov/Archives/edgar/data/1556263/000110465920096870/0001104659-20-096870-index.htm
2020-07-01SRINIVAS AKKARAJUDirectorSell4,627.0011.0150,965.941,433,943.00https://www.sec.gov/Archives/edgar/data/1556263/000110465920081190/0001104659-20-081190-index.htm
2020-06-25SRINIVAS AKKARAJUDirectorSell54,972.0011.15612,849.841,438,570.00https://www.sec.gov/Archives/edgar/data/1556263/000110465920076997/0001104659-20-076997-index.htm
2020-06-24SRINIVAS AKKARAJUDirectorSell48,775.0011.07539,788.051,493,542.00https://www.sec.gov/Archives/edgar/data/1556263/000110465920076997/0001104659-20-076997-index.htm
2020-06-23SRINIVAS AKKARAJUDirectorSell50,953.0011.11565,929.881,542,317.00https://www.sec.gov/Archives/edgar/data/1556263/000110465920076997/0001104659-20-076997-index.htm
2019-04-09SRINIVAS AKKARAJUDirectorBuy533,332.007.503,999,990.001,593,270.00https://www.sec.gov/Archives/edgar/data/1556263/000110465919020868/0001104659-19-020868-index.htm
2019-11-11Jeremy P. SpringhornChief Business OfficerBuy9,879.004.9949,327.8224,879.00https://www.sec.gov/Archives/edgar/data/1556263/000120919119056026/0001209191-19-056026-index.htm
2020-10-19Richard A YoungDirectorSell5,673.008.7549,638.75335,201.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120055334/0001209191-20-055334-index.htm
2020-10-15Richard A YoungDirectorSell317.008.752,773.75340,874.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120055059/0001209191-20-055059-index.htm
2020-09-15Richard A YoungDirectorSell5,990.0010.3962,236.10341,191.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120050618/0001209191-20-050618-index.htm
2020-08-17Richard A YoungDirectorSell5,990.0012.5975,414.10347,181.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120047501/0001209191-20-047501-index.htm
2019-11-12Jeremy P. SpringhornChief Business OfficerBuy10,121.004.9750,267.9735,000.00https://www.sec.gov/Archives/edgar/data/1556263/000120919119056026/0001209191-19-056026-index.htm
2020-07-15Richard A YoungDirectorSell5,990.0011.8570,981.50353,171.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120042796/0001209191-20-042796-index.htm
2020-06-15Richard A YoungDirectorSell5,990.008.7552,412.50359,161.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120037001/0001209191-20-037001-index.htm
2020-05-15Richard A YoungDirectorSell5,990.009.2255,242.18365,151.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120029763/0001209191-20-029763-index.htm
2020-04-15Richard A YoungDirectorSell23,960.008.75209,650.00371,141.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120024775/0001209191-20-024775-index.htm
2019-08-16Richard A YoungDirectorSell22,700.0010.00227,000.00395,101.00https://www.sec.gov/Archives/edgar/data/1556263/000120919119046516/0001209191-19-046516-index.htm
2019-08-15Richard A YoungDirectorSell2,300.0010.0023,000.00417,801.00https://www.sec.gov/Archives/edgar/data/1556263/000120919119046516/0001209191-19-046516-index.htm
2019-07-17ARCH Venture Fund VII, L.P.10% Share HolderSell34,521.007.70265,687.424,242,051.00https://www.sec.gov/Archives/edgar/data/1556263/000101297519000489/0001012975-19-000489-index.htm
2019-07-16ARCH Venture Fund VII, L.P.10% Share HolderSell25,779.007.81201,277.284,276,572.00https://www.sec.gov/Archives/edgar/data/1556263/000101297519000489/0001012975-19-000489-index.htm
2019-07-15ARCH Venture Fund VII, L.P.10% Share HolderSell2,700.008.2722,315.774,302,051.00https://www.sec.gov/Archives/edgar/data/1556263/000101297519000489/0001012975-19-000489-index.htm
2019-03-14ARCH Venture Fund VII, L.P.10% Share HolderSell43,000.008.15350,441.404,305,051.00https://www.sec.gov/Archives/edgar/data/1556263/000101297519000242/0001012975-19-000242-index.htm
2019-03-13ARCH Venture Fund VII, L.P.10% Share HolderSell2,820.008.2023,122.034,348,051.00https://www.sec.gov/Archives/edgar/data/1556263/000101297519000242/0001012975-19-000242-index.htm
2019-03-13ARCH Venture Fund VII, L.P.10% Share HolderSell81,591.007.89643,442.944,350,871.00https://www.sec.gov/Archives/edgar/data/1556263/000101297519000242/0001012975-19-000242-index.htm
2019-03-12ARCH Venture Fund VII, L.P.10% Share HolderSell40,092.007.37295,373.804,432,462.00https://www.sec.gov/Archives/edgar/data/1556263/000101297519000242/0001012975-19-000242-index.htm
2019-03-11ARCH Venture Fund VII, L.P.10% Share HolderSell44,878.006.49291,365.934,472,554.00https://www.sec.gov/Archives/edgar/data/1556263/000101297519000225/0001012975-19-000225-index.htm
2019-03-08ARCH Venture Fund VII, L.P.10% Share HolderSell84,496.006.93585,269.994,517,432.00https://www.sec.gov/Archives/edgar/data/1556263/000101297519000225/0001012975-19-000225-index.htm
2019-03-07ARCH Venture Fund VII, L.P.10% Share HolderSell35,209.006.87242,012.584,601,928.00https://www.sec.gov/Archives/edgar/data/1556263/000101297519000225/0001012975-19-000225-index.htm
2018-11-29Nancy A SimonianPresident & CEOBuy98,504.001.0199,489.04469,204.00https://www.sec.gov/Archives/edgar/data/1556263/000117911018013361/0001179110-18-013361-index.htm
2018-11-29Nancy A SimonianPresident & CEOBuy12,084.003.0436,735.36481,288.00https://www.sec.gov/Archives/edgar/data/1556263/000117911018013361/0001179110-18-013361-index.htm
2020-08-17Eric R OlsonChief Scientific OfficerBuy4,963.001.015,012.634,963.00https://www.sec.gov/Archives/edgar/data/1556263/000120919120047504/0001209191-20-047504-index.htm
2019-12-23Nancy A SimonianPresident & CEOBuy52,401.003.04159,299.04533,689.00https://www.sec.gov/Archives/edgar/data/1556263/000120919119061818/0001209191-19-061818-index.htm
2019-02-12Nancy A SimonianPresident & CEOBuy188,000.00669,288.00https://www.sec.gov/Archives/edgar/data/1556263/000120919119010287/0001209191-19-010287-index.htm
2019-02-12David RothChief Medical OfficerBuy87,000.0087,000.00https://www.sec.gov/Archives/edgar/data/1556263/000120919119010285/0001209191-19-010285-index.htm
2019-02-12Eric R OlsonChief Scientific OfficerBuy87,000.0087,000.00https://www.sec.gov/Archives/edgar/data/1556263/000120919119010283/0001209191-19-010283-index.htm
2019-02-12Gerald E QuirkChief Legal & Admin. OfficerBuy87,000.0087,000.00https://www.sec.gov/Archives/edgar/data/1556263/000120919119010284/0001209191-19-010284-index.htm
2019-02-12Joseph J Jr FerraChief Financial OfficerBuy87,000.0087,000.00https://www.sec.gov/Archives/edgar/data/1556263/000120919119010282/0001209191-19-010282-index.htm